Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation is about a user planning a blood test to monitor health while on hair loss treatments: Finasteride, Minoxidil, and Dutasteride. Recommendations include testing for androgens, thyroid function, micronutrients, and basic health markers, with additional suggestions for PSA, prolactin, and estradiol.

The conversation discusses the availability and legitimacy of a hair loss treatment called PP405-3HP. Users express skepticism about its release and reference patent information.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.

A 27-year-old male is using a hair loss treatment regimen including topical minoxidil, oral finasteride, dermarolling, ketoconazole shampoo, and mesotherapy with dutasteride and vitamins. He is considering switching to oral dutasteride as recommended by his doctor and questions the necessity and cost of mesotherapy.

Using dermaneedling or dermapen for hair loss while managing seborrheic dermatitis and dandruff. Treatments mentioned include ketoconazole, peppermint and jojoba oil, and rubbing alcohol.

The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.

The user has been using dutasteride and oral minoxidil for hair loss but hasn't seen significant improvement. Suggestions include adding microneedling, checking for vitamin deficiencies, and considering a stronger dutasteride dosage.

The user has been using oral minoxidil and dutasteride for hair loss without success and is considering adding topical 17α-estradiol, Pyrilutamide, Clascoterone, or cetirizine. They have confirmed low serum DHT levels and are exploring additional treatments due to genetic sensitivity to DHT and prostaglandin D2.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

A 22-year-old male has been using oral dutasteride, oral minoxidil, topical minoxidil, and supplements for hair loss, experiencing shedding but some regrowth on the temples. Despite concerns about starting dutasteride, he is seeing positive results and hopes for long-term success.

CB-03-01, also known as Breezula, is being considered as an alternative to DHT blockers for hair loss. Users are discussing its effectiveness, potential regrowth, side effects like scalp irritation, and hormonal impacts.

A 21-year-old male diagnosed with telogen effluvium and male pattern baldness started oral finasteride, which initially slowed hair loss and slightly thickened hair, but experienced increased shedding after surgery. The doctor recommended iron and vitamin D supplements, and the user is seeking additional advice.

Topical Dutasteride, especially in a liposomal base, is recommended for enhanced scalp DHT suppression when used with oral Dutasteride. It is suggested to apply it twice a week for effective results without significant systemic impact.

The conversation is about the availability of the PP405 formula for hair loss treatment, with mentions of finasteride and its side effects. Users discuss the potential of obtaining the formula through unofficial channels and the challenges related to its genetic sequence and delivery method.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

Pelage Pharmaceuticals is starting Phase 3 trials for PP405 in September 2026, with potential market release by 2030. Users discuss various hair loss treatments like minoxidil, finasteride, RU58841, kx, breezula, and gt20029, expressing hope for future hair restoration.

People are discussing the potential of a new hair loss treatment, pp405, and its approval timeline, comparing it to existing treatments like Minoxidil and finasteride. There is skepticism about its effectiveness and concerns about the time it will take for approval and availability, especially in Europe.

A hair restoration case involved injecting four different doses of Verteporfin into the mid scalp and using Scalp MicroPigmentation (SMP) around the extraction areas. Photos were taken and an update will be shared soon.

The user has been using finasteride, dutasteride, minoxidil, and a dermaroller/dermastamp for hair loss, reporting positive results and no significant side effects. They switched from finasteride to dutasteride for better results and apply topical minoxidil despite having braids.

Cecred hair drops, containing keratin and biotin, are questioned for their effectiveness compared to proven treatments like minoxidil. Users express skepticism, suggesting deceptive marketing and the possibility of undisclosed use of other treatments like finasteride.

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

The conversation discusses DIY topical finasteride, with users sharing experiences and advice on dissolving crushed pills in a solvent. Some recommend using raw finasteride powder or buying pre-made solutions for better stability and effectiveness.

ET-02 is seen as promising for addressing hair loss and graying, but PP405 is more advanced in development and has better publicity. Some users plan to use both treatments alongside minoxidil and dutasteride.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

A poem humorously suggests hope for a new hair loss treatment, PP405, while users debate the effectiveness and side effects of current treatments like Finasteride. Concerns are raised about Finasteride's side effects, especially for young users, and skepticism about new treatments is expressed.

The user switched to dutasteride and saw palmetto, along with a topical mix of minoxidil and finasteride, due to continued hair shedding. They hope for improvement despite concerns about saw palmetto's effectiveness.

The user has been using finasteride and dutasteride for hair loss but is experiencing low energy and motivation, possibly due to high prolactin levels. Despite treatment, hairline recession continues, and the user is considering the impact of low DHT levels on overall health and energy.

Finasteride's effectiveness and side effects may vary based on male phenotypes, with some users noting differences in response related to body and facial hair characteristics. Some users report success with lower doses, while others experience side effects, suggesting individual variability in response to the treatment.

The conversation discusses the impact of hair loss treatments like dutasteride and finasteride, with some users expressing skepticism about media claims linking these drugs to severe side effects like suicidal ideation. Many participants criticize the media, particularly British tabloids, for fearmongering and emphasize the psychological impact of hair loss itself.